Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | SYK | P43405 | 2/20 | 0.52 |
| ▸ | JAK3 | P52333 | 6/20 | 0.51 |
| ▸ | JAK2 | O60674 | 5/20 | 0.51 |
| ▸ | JAK1 | P23458 | 4/20 | 0.51 |
| ▸ | TYK2 | P29597 | 4/20 | 0.51 |
| ▸ | AURKA | O14965 | 4/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1018676 | 0.93 | JAK3 (0.57) | SYKJAK3JAK2JAK1TYK2 | |
| SCHEMBL12085397 | 0.88 | SYK (0.52) | GSK3AGSK3BSYKJAK3JAK2 | |
| SCHEMBL1017694 | 0.84 | CCNE1 (0.52) | SYKJAK2JAK1TYK2AURKA | |
| SCHEMBL1018292 | 0.84 | SYK (0.50) | SYKJAK3JAK2JAK1TYK2 | |
| SCHEMBL1017426 | 0.84 | SYK (0.58) | SYK | |
| SCHEMBL4302281 | 0.83 | JAK3 (0.53) | SYKJAK3JAK2JAK1TYK2 | |
| SCHEMBL1018107 | 0.81 | JAK3 (0.54) | SYKJAK3JAK2JAK1TYK2 | |
| SCHEMBL1018052 | 0.80 | SYK (0.51) | SYKNPC1RAB9ASMN1; SMN2BRD4 | |
| SCHEMBL1018051 | 0.79 | JAK3 (0.52) | JAK3JAK2JAK1TYK2AURKA | |
| SCHEMBL12085297 | 0.79 | CCNA2 (0.46) | GSK3AGSK3BSYKJAK3AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271631-A2 | INHIBITORS OF PROTEIN KINASES | Portola Pharmaceuticals, Inc. (US) | 2011-01-12 | — | — | EP | claimed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | claimed |
| WO-2009131687-A2 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | claimed |
| EP-2271631-B1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARM INC (US) | 2018-07-04 | — | — | EP | disclosed |
| US-9139581-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139581-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139581-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8258144-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258144-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258144-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2271631-A2 | INHIBITORS OF PROTEIN KINASES | Portola Pharmaceuticals, Inc. (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2009131687-A2 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK2 | GSK3A 288/4885GSK3B 247/4885SYK 1/4885 |
| US-20090298823-A1 | Inhibitors of protein kinases | SYK, BTK, JAK2 | GSK3A 288/4885GSK3B 247/4885SYK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.